These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 11661914)
21. Position statement of the AFCR on FDA proposal to assign scientific review of new drugs for human use to local institutional review boards. American Federation for Clinical Research Clin Res; 1982 Feb; 30(1):27-8. PubMed ID: 11653562 [No Abstract] [Full Text] [Related]
22. Experimental drugs: more of them, but they're no longer free. Caplan J Hastings Cent Rep; 1987 Jun; 17(3):3. PubMed ID: 11644019 [No Abstract] [Full Text] [Related]
23. Implications of the federal drug investigation and approval processes for the development and availability of AIDS treatments and vaccines. Mathers PR AIDS Public Policy J; 1987; 2(2):50-3. PubMed ID: 11650030 [No Abstract] [Full Text] [Related]
24. Resolution: RU 486. American Association for the Advancement of Science Science; 1991 Apr; 252(5005):587. PubMed ID: 11642875 [No Abstract] [Full Text] [Related]
25. The abortion cocktail. Nathanson BN First Things; 1996 Jan; 59():23-6. PubMed ID: 11656484 [No Abstract] [Full Text] [Related]
26. The politics of research misconduct: congressional oversight, universities, and science. LaFollette MC J Higher Educ; 1994; 65(3):261-85. PubMed ID: 11653364 [No Abstract] [Full Text] [Related]
27. Faith (healing), hope and charity at the FDA: the politics of AIDS drug trials. Annas GJ Villanova Law Rev; 1989 Sep; 34(5):771-97. PubMed ID: 11651162 [No Abstract] [Full Text] [Related]
28. Health Research Extension Act of 1985. Public Law 99-158. United States US Statut Large; 1985; 99(Title IV Sections 1-12):. PubMed ID: 11686169 [No Abstract] [Full Text] [Related]
29. Women and HIV/AIDS research: the barriers to equity. Levine C IRB; 1991; 13(1-2):18-22. PubMed ID: 11659324 [No Abstract] [Full Text] [Related]
31. Getting new drugs to people with AIDS: a public policy response to Lansdale. Cohen MN Hastings Constit Law Q; 1991; 18(3):471-85. PubMed ID: 11651493 [No Abstract] [Full Text] [Related]
32. Worries about animal models in biomedical research: a response to LaFollette and Shanks. Willis LR; Hulsey MG Public Aff Q; 1994 Apr; 8(2):205-18. PubMed ID: 11652920 [No Abstract] [Full Text] [Related]
34. Can (or should) the IRB assume the FDA's functions at early stages of the IND process? Levine RJ IRB; 1981 Dec; 3(10):4-5. PubMed ID: 11649414 [No Abstract] [Full Text] [Related]
35. Innovation and integrity in biomedical research. Jasanoff S Acad Med; 1993 Sep; 69(9 Suppl):S91-5. PubMed ID: 11652808 [No Abstract] [Full Text] [Related]
36. In search of funding: the clinical investigator and the drug company; Commentary: why researchers need not be demoralized. Siris ES; Burrell CD IRB; 1983; 5(6):1-5. PubMed ID: 11649526 [No Abstract] [Full Text] [Related]
37. The war on cancer: first do no harm. Part 2: Risk, rivalry and research--and error. Neumann J; Gup T Washington Post; 1981 Oct; ():A1, A26, A27. PubMed ID: 11646112 [No Abstract] [Full Text] [Related]
38. In business to treat cancer. Henig RM N Y Times Mag; 1986 Nov; ():68, 70, 78, 80+. PubMed ID: 11647805 [No Abstract] [Full Text] [Related]
39. Shaking up the status quo: how AIDS activists have challenged drug development and approval procedures. Dunbar MM Food Drug Cosmet Law J; 1991 Sep; 46(5):673-706. PubMed ID: 11651380 [No Abstract] [Full Text] [Related]